Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Symbol: ESPR on Nasdaq
Shares outstanding: 207,440,936
Price per share: $3.55
All holders as of 31 Dec 2025: Q4 2025
Total 13F shares: 150,478,613
Total reported value: $556,711,242
% of total 13F portfolios: 0%
Share change: +43,225,542
Value change: +$164,489,962
Number of holders: 195
Price from insider filings: $3.55

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Two Seas Capital LP	4.7%	-6%	$25,836,769	-$543,915	9,749,724	-2.1%	Two Seas Capital LP	30 Sep 2025
BB BIOTECH AG	4.9%	-2%	$8,821,598	-$227,500	9,694,064	-2.5%	BB Biotech AG	04 Mar 2025
WASATCH ADVISORS LP	3.5%	-33%	$18,713,921	-$10,253,910	7,061,857	-35%	Wasatch Advisors LP	30 Sep 2025

As of 31 Dec 2025, 195 institutional investors reported holding 150,478,613 shares of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR). This represents 73% of the company’s total 207,440,936 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
BlackRock, Inc.	8.5%	17,682,201	+19%	0%	$65,424,144
VANGUARD GROUP INC	7.2%	14,945,454	+24%	0%	$55,298,179
Two Seas Capital LP	5.7%	11,902,521	+22%	2.6%	$44,039,328
WASATCH ADVISORS LP	4.6%	9,445,759	+34%	0.21%	$34,949,308
D. E. Shaw & Co., Inc.	3.3%	6,903,483	+3209%	0.02%	$25,542,887
ORBIMED ADVISORS LLC	2.9%	5,965,498		0.47%	$22,072,343
STATE STREET CORP	2.9%	5,930,296	+32%	0%	$21,942,095
GEODE CAPITAL MANAGEMENT, LLC	2.8%	5,737,651	+21%	0%	$21,233,711
MARSHALL WACE, LLP	2.6%	5,471,611	+117%	0.02%	$20,244,963
TWO SIGMA INVESTMENTS, LP	2.3%	4,742,082	+112%	0.03%	$17,545,703
PenderFund Capital Management Ltd.	2.1%	4,391,926	-34%	2.6%	$16,250,126
AIGH Capital Management LLC	1.9%	4,000,000	+33%	4.4%	$14,800,000
MILLENNIUM MANAGEMENT LLC	1.9%	3,932,274	+303%	0.01%	$14,549,414
Eversept Partners, LP	1.9%	3,851,133		0.8%	$14,249,192
Nuveen, LLC	1.7%	3,612,113	-2.7%	0%	$13,364,818
ROYCE & ASSOCIATES LP	1.7%	3,601,523	+57%	0.14%	$13,325,635
MORGAN STANLEY	1.7%	3,514,227	-13%	0%	$13,002,640
TWO SIGMA ADVISERS, LP	1.7%	3,505,200	+84%	0.03%	$12,969,240
GOLDMAN SACHS GROUP INC	1.4%	2,848,216	+67%	0%	$10,538,400
RENAISSANCE TECHNOLOGIES LLC	1.1%	2,194,600	+184%	0.01%	$8,120,020
JONES FINANCIAL COMPANIES LLLP	1%	2,094,412	+167721%	0%	$7,749,324
NORTHERN TRUST CORP	0.96%	1,995,706	+8%	0%	$7,384,113
Walleye Capital LLC	0.76%	1,569,216	+392%	0.03%	$5,806,099
Velan Capital Investment Management LP	0.58%	1,210,000		2.6%	$4,477,000
Voleon Capital Management LP	0.56%	1,154,390	+455%	0.09%	$4,271,243

Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	150,478,613	$556,711,242	+$164,489,962	$3,557,550	$15,474,844	$3.70	195
2025 Q3	108,004,285	$286,206,908	+$32,005,545	$2,036,629	$1,703,688	$2.65	188
2025 Q2	98,221,986	$96,659,560	-$21,194,525	$593,373	$137,265	$0.98	161
2025 Q1	111,244,473	$160,207,390	-$24,300,645	$977,040	$247,734	$1.44	183
2024 Q4	126,046,299	$277,285,420	+$4,393,183	$2,794,970	$3,375,060	$2.20	188
2024 Q3	128,986,677	$212,839,069	-$18,982,245	$1,534,545	$2,351,640	$1.65	181
2024 Q2	136,753,565	$303,582,298	+$17,706,459	$2,896,686	$5,501,715	$2.22	173
2024 Q1	125,253,343	$335,669,495	+$141,351,114	$2,705,728	$4,906,812	$2.68	147
2023 Q4	71,634,221	$214,185,830	-$13,154,422	$1,774,864	$5,722,561	$2.99	127
2023 Q3	77,232,361	$75,678,982	-$1,733,880	$182,182	$1,100,050	$0.98	120
2023 Q2	74,286,796	$103,280,736	-$10,483,186	$500,817	$1,818,831	$1.39	121
2023 Q1	80,929,285	$128,750,548	-$22,081,506	$1,293,783	$3,650,175	$1.59	161
2022 Q4	73,478,005	$457,748,937	+$39,215,603	$8,737,748	$35,734,299	$6.23	164
2022 Q3	62,444,882	$418,381,560	+$53,328,619	$3,171,000	$14,288,000	$6.70	143
2022 Q2	55,366,705	$352,132,262	+$24,287,037	$1,619,000	$6,445,000	$6.36	128
2022 Q1	51,922,058	$241,219,302	-$10,656,706	$1,019,000	$3,535,000	$4.64	121
2021 Q4	53,613,124	$268,022,905	+$97,310,967	$2,661,000	$2,201,000	$5.00	119
2021 Q3	24,797,305	$298,815,522	-$61,530,602	$11,001,000	$6,235,000	$12.05	133
2021 Q2	28,340,478	$599,385,890	-$18,947,335	$17,536,000	$7,578,000	$21.15	140
2021 Q1	28,702,213	$805,059,737	-$64,474,348	$17,643,500	$5,512,000	$28.05	151
2020 Q4	30,878,165	$802,895,778	-$34,208,444	$14,328,000	$9,367,000	$26.00	152
2020 Q3	31,640,175	$1,176,015,102	-$28,756,691	$15,472,000	$23,290,000	$37.17	165
2020 Q2	31,971,491	$1,640,380,010	+$123,898,647	$24,901,327	$27,815,174	$51.31	179
2020 Q1	29,570,957	$916,082,618	+$53,953,340	$12,186,000	$7,914,000	$31.53	157
2019 Q4	27,848,044	$1,621,473,992	+$45,891,970	$27,533,000	$36,219,000	$59.63	170
2019 Q3	27,027,940	$990,522,973	-$72,172,854	$16,451,000	$16,089,000	$36.66	145
2019 Q2	28,447,747	$1,323,221,426	+$216,701,139	$20,800,000	$22,651,000	$46.52	166
2019 Q1	27,588,882	$1,107,641,121	+$27,039,632	$22,560,000	$12,952,000	$40.15	160
2018 Q4	26,812,324	$1,233,297,022	-$65,824,574	$20,580,000	$28,851,000	$46.00	152
2018 Q3	28,254,155	$1,253,898,089	-$106,658,510	$58,823,000	$31,309,000	$44.37	151
2018 Q2	30,817,874	$1,207,760,885	+$133,006,694	$45,703,000	$13,362,000	$39.19	151
2018 Q1	26,467,526	$1,914,388,196	+$178,186,545	$78,756,000	$75,187,000	$72.33	184
2017 Q4	24,011,278	$1,580,908,389	+$28,478,384	$34,647,000	$32,748,000	$65.84	163
2017 Q3	24,158,062	$1,210,838,699	+$158,389,093	$32,708,000	$12,892,000	$50.12	150
2017 Q2	20,787,063	$962,036,441	+$142,703,625	$95,557,000	$25,348,000	$46.28	129
2017 Q1	17,982,623	$634,962,044	+$201,687,554	$47,630,000	$13,986,000	$35.31	116
2016 Q4	14,790,757	$185,178,042	+$1,997,113	$661,000	$2,975,000	$12.52	96
2016 Q3	14,434,779	$199,910,330	-$703,426	$1,327,000	$1,417,000	$13.85	98
2016 Q2	14,667,103	$144,916,054	-$27,764,688	$1,459,000	$837,000	$9.88	98
2016 Q1	15,788,626	$266,644,000	-$13,544,152	$1,993,000	$3,276,000	$16.91	104
2015 Q4	16,427,090	$365,743,034	-$11,898,095	$3,314,000	$2,620,000	$22.26	111
2015 Q3	16,611,937	$391,855,349	-$215,978,223	$9,801,000	$9,693,000	$23.59	120
2015 Q2	15,304,049	$1,251,247,346	+$182,794,461	$51,826,000	$133,483,000	$81.76	150
2015 Q1	12,803,656	$1,185,461,048	+$474,650,240	$35,624,000	$42,825,000	$92.60	139
2014 Q4	7,779,336	$314,790,098	+$168,789,584	$1,747,000	$2,426,000	$40.44	82
2014 Q3	3,501,400	$85,642,436	+$3,067,413			$24.46	49
2014 Q2	5,556,294	$88,004,478	+$33,701,269			$15.84	43
2014 Q1	3,430,835	$51,872,345	+$961,180			$15.12	40